This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
This week, the Cleveland Clinic enrolled the first patient in the AVANT GUARD trial, overseen by Dr. Oussama Wazni, vice chair of cardiovascular medicine and section head, Cardiac Electrophysiology and Pacing, Cleveland Clinic, who is also serving as the lead investigator of the trial. Circulation.
Innovation in medical technology exists to improve patient outcomes, increase surgical efficiency and enhance patient safety. Infrequently, we see medical technology innovation of a paradigmatic nature that changes the way physicians approach disease states and dramatically improve results.
Atrialfibrillation (AF) is the most common arrhythmia worldwide, with increasing prevalence resulting from improved awareness, increased life expectancy, and advances in detection technology.
The first procedures, performed by leading physicians Saibal Kar , MD, FACC, FSCAI, (Program Director, Cardiovascular Disease Fellowship, Los Robles Health System , California, HCA Healthcare National Physician Director, Interventional Cardiology) and Devi Nair , MD, FACC, FHRS, (Director, Cardiac Electrophysiology Division, St.
intermittent) atrialfibrillation (AF) and is a unique new alternative to standard-of-care thermal ablation treatment. intermittent) atrialfibrillation (AF) and is a unique new alternative to standard-of-care thermal ablation treatment. said Nick Spadea-Anello, president, Electrophysiology, Boston Scientific. "The
Abstract Introduction Atrialfibrillation (Afib) is a prevalent chronic arrhythmia associated with severe complications, including stroke, heart failure, and increased mortality. Despite ethical considerations and disparities, the potential benefits outweigh the challenges.
FDA approval for the navigation-enabled FARAWAVE NAV Ablation Catheter for the treatment of paroxysmal atrialfibrillation and FDA 510(k) clearance for the new FARAVIEW Software, which will combine to provide visualization for cardiac ablation procedures with the FARAPULSE Pulsed Field Ablation System.
The Heart Rhythm Society (HRS) is preparing for HRX 2024, the third annual event of its kind, which will be held from September 5-7, 2024, in Atlanta, GA, gathering cardiovascular health innovators together to explore discoveries and advance partnerships between medicine and technology. On Thursday, Sept.
1 Catheter ablation for atrialfibrillation (AF) and ventricular tachycardia (VT) has become the standard of care for many patients presenting with these arrhythmias.2–4 1 Catheter ablation for atrialfibrillation (AF) and ventricular tachycardia (VT) has become the standard of care for many patients presenting with these arrhythmias.2–4
a company primarily focused on leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment of atrialfibrillation, announced the completion of the first five procedures in its first-in-human feasibility study with its novel CellFX nsPFA cardiac catheter.
Abstract Introduction Catheter ablation of atrialfibrillation (AF) has emerged as the most effective therapy. Conclusions It is a feasible and safe approach with support of transesophageal echocardiography and multiple emerging technologies.
The most common arrhythmia, atrialfibrillation , will affect approximately 12.1 Food and Drug Administration (FDA) in July 2023, a new leadless pacemaker system placed in both chambers of the heart and using a novel communication technology is now offering a more minimally invasive option for patients. Approved by the U.S.
Among the four studied technologies, PFA was associated with the shortest procedure duration, the highest myocardial injury, and the lowest level of inflammation. Abstract Introduction Pulmonary vein isolation (PVI) using radiofrequency ablation (RFA) is an established treatment strategy for atrialfibrillation (AF).
Abstract Introduction Despite advanced ablation strategies and major technological improvements, treatment of persistent atrialfibrillation (AF) remains challenging and the underlying pathophysiology is not fully understood.
24 will focus on the following three current guideline updates: American College of Cardiology (ACC)/American Heart Association (AHA) Guidelines 2023 AtrialFibrillation Guideline - Pharmacology II: Strokes vs. Bleeds, What Do the Guidelines Tell Us About Practical Management in A-fib? The Guidelines Sessions at ACC.24
OSA is commonly seen in patients with arrhythmias like atrialfibrillation (AFib) and due to the variable unpredictable nature of sleep apnea symptoms, it is often untreated, leading to adverse outcomes. Western Regional Director of Cardiac Electrophysiology, Northwell Health , NY. David's Medical Center.
This study aims to identify factors leading to insufficient lesions during pulmonary vein antral isolation (PVAI) with vHPSD-ablation and to develop an optimized PVAI strategy using this technology. Methods PVAI was performed on 41 atrialfibrillation patients using vHPSD-ablation (90W/4s).
Matched control cases were enrolled in reverse chronological order beginning on the last day for which the technology was unavailable. Results The study group consisted of 28 patients (age 65 ± 11 years, 46% female, left atrial dimension 4.1 ± 0.9 cm, cm, LVEF 50 ± 18%) and was similar to 28 controls. vs. 33.2 ± 18.0
Abstract Background The newly introduced nonthermal pulsed field ablation (PFA) is a promising technology to achieve fast pulmonary vein isolation (PVI) with high acute success rates and good safety features. PFA versus VHPSD for PVI. Data comparing PFA to VHPSD-PVI is lacking. For PFA-PVI a pentaspline 20 electrode catheter was used.
In particular, the study showed superiority in the percentage of patients that achieved freedom from atrialfibrillation (AF) with or without anti-arrhythmic drugs at 12 months after a tailored cardiac ablation guided by AI in combination with PVI when compared to PVI alone. tim.hodson Fri, 02/14/2025 - 09:57 Feb. adult population.
During its Annual Conference, HRS 2024, the Heart Rhythm Society (HRS) announced findings from three new studies demonstrating the safety and efficacy of pulsed field ablation (PFA), a nonthermal ablation treatment for patients with atrialfibrillation (AF). See full findings from the FARADISE, admIRE Study, and Advent Trial here.
Volta Medical has announced it has entered into a Joint Development Agreement with GE Healthcare to enhance arrhythmia procedures with artificial intelligence (AI)-driven electrophysiologytechnologies. Estimates of current and future incidence and prevalence of atrialfibrillation in the U.S. adult population.
This is the first PFA technology to receive FDA approval and follows the recent European CE (Conformité Européenne) Mark of the PulseSelect PFA system in November. This is the first PFA technology to receive FDA approval and follows the recent European CE (Conformité Européenne) Mark of the PulseSelect PFA system in November.
milla1cf Fri, 02/02/2024 - 17:18 February 2, 2024 — GE HealthCare (Nasdaq: GEHC) announces the latest innovation in electrophysiology (EP), the Prucka 3 with CardioLab EP Recording system, to help clinicians in the diagnosis and treatment of cardiac arrhythmias. Usman Siddiqui , Director of Electrophysiology. [5]
tim.hodson Thu, 03/27/2025 - 12:18 March 27, 2025 Abbott recently announced it has received CE Mark in Europe for the Volt PFA System to treat patients battling atrialfibrillation (AFib). The One System Solution provided by EnSite X can accommodate all EP procedures and compatible technologies. 1 Fact Sheets for Press.
An international consensus statement on how to treat atrialfibrillation with catheter or surgical ablation has been published in EP Europace, a journal of the European Society of Cardiology (ESC), and was recently presented at EHRA 2024, a scientific congress held April 7-9 in Berlin, Germany.
milla1cf Mon, 02/12/2024 - 15:18 February 12, 2024 — BIOTRONIK , a leader in implantable medical device technology, announced today they will solely supply their proprietary DX models for new single-chamber ICD implants moving forward. Journal of Cardiovascular Electrophysiology, Volume 30, Issue 10, October 2019, Pages 1994–2001.
The transaction follows Johnson & Johnson MedTech’s successful acquisitions of Abiomed , a leader in heart recovery, and more recently Laminar, an innovator in left atrial appendage elimination for patients with non-valvular atrialfibrillation (AFib).
By the 1960s, advances in technology and medical research led to the emergence of automated ECG interpretation (AEI), based on physician-developed rules of classification. By 1909 ECGs were being used to diagnose cases of arrhythmia; by 1910 to diagnose indicators of a heart attack.
a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTech , today announced European CE mark approval of the VARIPULSE Platform for the treatment of symptomatic drug refractory recurrent paroxysmal atrialfibrillation ( AF ) using pulsed field ablation (PFA). AtrialFibrillation. Circulation.
ABSTRACT Introduction Pulmonary vein isolation (PVI) using a cryoballoon is well-established for the treatment of paroxysmal atrialfibrillation (PAF). Compared to other available technologies, the usage of a stable, low-pressure cryoballoon (POLARx, Boston Scientific) has demonstrated lower nadir temperatures and longer thawing times.
Abstract Introduction Pulsed field ablation (PFA) is a new ablation technology for atrialfibrillation (AF). Data regarding early recurrences of atrial tachyarrhythmia (ERAT) after PFA-pulmonary vein isolation (PVI) are sparse. Methods Consecutive patients with symptomatic AF were enrolled to undergo PFA-PVI.
Helmsley Charitable Trust Professor of Medicine in Cardiac Electrophysiology at Icahn Mount Sinai. Dr. Reddy serves as an unpaid consultant to Boston Scientific, the manufacturer of the PFA catheter technology studied in this manuscript. and Harry B.
Institutional Coronary Artery Bypass Case Volumes and Outcomes European Journal of Heart Failure October 2023 Makoto Mori Robotic Mitral Valve Repair for Degenerative Mitral Regurgitation The Annals of Thoracic Surgery August 2023 Carlos Diaz-Castrillion Volume-Failure to Rescue Relationship in Acute Type A Aortic Dissections: An Analysis of The Society (..)
Boston Scientific made what could become a major addition to its electrophysiology portfolio, acquiring AFib mapping startup Cortex, Inc. Cortex gives Boston Scientific a new mapping technology that detects AFib signs and triggers outside of the pulmonary veins, and can help EP teams develop ablation strategies for more complex AFib cases.
ABSTRACT Background Factors contributing to early recurrence after atrialfibrillation (AF) ablation, particularly with pulsed-field ablation (PFA), are poorly understood. Trial Registration: Advanced TecHnologies For SuccEssful AblatioN of AF in Clinical Practice (ATHENA). URL: [link]. Identifier: NCT05617456.
With this approval, Medtronic now offers two PFA technologies available for patients with Afib. The Affera system was designed to address procedural challenges faced by the electrophysiology community while maintaining a high standard of safety and efficacy for patients. tim.hodson Wed, 10/30/2024 - 13:42 Oct.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content